IN2014DN07812A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN07812A IN2014DN07812A IN7812DEN2014A IN2014DN07812A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A IN 7812DEN2014 A IN7812DEN2014 A IN 7812DEN2014A IN 2014DN07812 A IN2014DN07812 A IN 2014DN07812A
- Authority
- IN
- India
- Prior art keywords
- reprogramming
- methods
- marks
- epigenetic
- mark readers
- Prior art date
Links
- 230000008672 reprogramming Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001973 epigenetic effect Effects 0.000 abstract 2
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 abstract 1
- 101000797586 Homo sapiens Chromobox protein homolog 2 Proteins 0.000 abstract 1
- 101000934489 Homo sapiens Nucleosome-remodeling factor subunit BPTF Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100025062 Nucleosome-remodeling factor subunit BPTF Human genes 0.000 abstract 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computing Systems (AREA)
- Biophysics (AREA)
- Library & Information Science (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603650P | 2012-02-27 | 2012-02-27 | |
| US201261637282P | 2012-04-24 | 2012-04-24 | |
| PCT/CA2013/050145 WO2013127011A1 (en) | 2012-02-27 | 2013-02-27 | Reprogramming effector protein interactions to correct epigenetic defects in cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07812A true IN2014DN07812A (pm) | 2015-05-15 |
Family
ID=49081499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7812DEN2014 IN2014DN07812A (pm) | 2012-02-27 | 2013-02-27 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9552457B2 (pm) |
| EP (1) | EP2819662B1 (pm) |
| JP (1) | JP6137703B2 (pm) |
| KR (1) | KR102149860B1 (pm) |
| CN (1) | CN104136020B (pm) |
| AU (1) | AU2013225592B2 (pm) |
| BR (1) | BR112014021201B1 (pm) |
| CA (1) | CA2865675C (pm) |
| IN (1) | IN2014DN07812A (pm) |
| RU (1) | RU2637441C2 (pm) |
| WO (1) | WO2013127011A1 (pm) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971129B1 (en) | 2013-03-15 | 2018-05-09 | Sutter Bay Hospitals | Falz for use as a target for therapies to treat cancer |
| CN105873588A (zh) * | 2013-09-09 | 2016-08-17 | 戈里奥诺瓦公司 | 用于治疗癌症的化合物和其用途 |
| EP3064205A1 (en) * | 2015-03-06 | 2016-09-07 | Glionova AB | Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol |
| CA2980393A1 (en) * | 2015-03-18 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Methods for diagnosing and treating follicular lymphoma |
| JP6862418B2 (ja) | 2015-07-31 | 2021-04-21 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | センサ、カートリッジ、および薬物送達デバイス |
| JP2021501198A (ja) * | 2017-10-27 | 2021-01-14 | トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー | フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 |
| WO2022081892A1 (en) * | 2020-10-14 | 2022-04-21 | The Regents Of The University Of California | Systems for and methods of determining protein-protein interaction |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE603039A (pm) | 1960-04-26 | |||
| GB1120463A (en) | 1964-07-06 | 1968-07-17 | Manuf Prod Pharma | Derivatives of 1,3-diazafluoranthene-1-oxide |
| US3622580A (en) | 1969-03-25 | 1971-11-23 | Smith Kline French Lab | Piperazino-acetylamino-9-fluorenones and-anthraquinones |
| LU85246A1 (fr) | 1984-03-13 | 1985-10-14 | R L Galephar Sa | 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation |
| US5501959A (en) | 1989-01-17 | 1996-03-26 | Alamar Biosciences Laboratory, Inc. | Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents |
| AU4218799A (en) * | 1998-08-25 | 2000-03-14 | Scripps Research Institute, The | Methods and systems for predicting protein function |
| US7928218B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) |
| EP2865381A1 (en) * | 2006-05-18 | 2015-04-29 | Pharmacyclics, Inc. | ITK inhibitors for treating blood cell malignancies |
| WO2009015283A2 (en) | 2007-07-24 | 2009-01-29 | President And Fellows Of Harvard College | Bhc80 - histone complexes and uses thereof |
| CN104557914A (zh) | 2008-09-26 | 2015-04-29 | 新加坡科技研究局 | 3-脱氮瓶菌素衍生物 |
| WO2010045199A2 (en) | 2008-10-13 | 2010-04-22 | University Of South Florida | Method of modulating ship activity |
| GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
| WO2010094009A2 (en) | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
| CA2769038A1 (en) * | 2009-07-31 | 2011-02-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Antiangiogenic small molecules and methods of use |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| ES2534521T3 (es) | 2010-05-14 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012123119A1 (en) | 2011-03-17 | 2012-09-20 | Cellzome Ag | Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins |
| WO2013059944A1 (en) | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
-
2013
- 2013-02-27 IN IN7812DEN2014 patent/IN2014DN07812A/en unknown
- 2013-02-27 EP EP13754077.9A patent/EP2819662B1/en active Active
- 2013-02-27 KR KR1020147027072A patent/KR102149860B1/ko not_active Expired - Fee Related
- 2013-02-27 BR BR112014021201-5A patent/BR112014021201B1/pt not_active IP Right Cessation
- 2013-02-27 US US14/381,588 patent/US9552457B2/en not_active Expired - Fee Related
- 2013-02-27 CN CN201380011304.1A patent/CN104136020B/zh not_active Expired - Fee Related
- 2013-02-27 CA CA2865675A patent/CA2865675C/en active Active
- 2013-02-27 JP JP2014557953A patent/JP6137703B2/ja not_active Expired - Fee Related
- 2013-02-27 WO PCT/CA2013/050145 patent/WO2013127011A1/en active Application Filing
- 2013-02-27 AU AU2013225592A patent/AU2013225592B2/en not_active Ceased
- 2013-02-27 RU RU2014138543A patent/RU2637441C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2637441C2 (ru) | 2017-12-04 |
| CN104136020A (zh) | 2014-11-05 |
| AU2013225592A1 (en) | 2014-10-09 |
| KR102149860B1 (ko) | 2020-08-31 |
| AU2013225592B2 (en) | 2017-11-09 |
| CA2865675A1 (en) | 2013-09-06 |
| AU2013225592A2 (en) | 2014-10-09 |
| EP2819662A1 (en) | 2015-01-07 |
| CA2865675C (en) | 2023-02-28 |
| RU2014138543A (ru) | 2016-04-20 |
| KR20140132382A (ko) | 2014-11-17 |
| EP2819662A4 (en) | 2016-03-23 |
| US9552457B2 (en) | 2017-01-24 |
| CN104136020B (zh) | 2018-08-28 |
| JP2015515448A (ja) | 2015-05-28 |
| WO2013127011A1 (en) | 2013-09-06 |
| BR112014021201B1 (pt) | 2023-01-24 |
| BR112014021201A2 (pt) | 2021-06-08 |
| US20150154345A1 (en) | 2015-06-04 |
| EP2819662B1 (en) | 2019-04-10 |
| JP6137703B2 (ja) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07812A (pm) | ||
| BR112015020650A2 (pt) | inibidores de histona demetilases | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| GEP20166554B (en) | Nitrogenated heterocyclic compound | |
| BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
| NZ706635A (en) | Inhibitors of histone demethylases | |
| PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
| PH12013500258B1 (en) | Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds | |
| MX381260B (es) | Inhibidores heterociclicos de glutaminasa. | |
| WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
| BR112016002069A2 (pt) | novo composto de pirimidina fusionada ou sal deste | |
| MX369562B (es) | Cateter con marcas para facilitar alineacion. | |
| TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
| PH12012501402A1 (en) | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | |
| BR112015018047A2 (pt) | composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão | |
| GB2514714A (en) | Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue | |
| MX354598B (es) | Uso de neuregulina para tratar lesion de nervio periferico. | |
| CL2015003563A1 (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos. | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| IN2014DN09584A (pm) | ||
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| TN2015000020A1 (en) | Molecular markers and methods for early sex determination in date palms | |
| MX2018010829A (es) | Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial. | |
| WO2014029888A3 (en) | Branched or macrocyclic polyamines and uses thereof | |
| WO2011103028A3 (en) | Compositions and methods for inhibiting mmset |